Elderly patients with advanced colorectal cancer: Which therapy is the safest?

Expert Opinion on Drug Safety

Volumn 4, Issue 6, 2005, Pages 1041-1049

  Rosati, Gerardo ^a  

^a SAN CARLO HOSPITAL   (Italy)

Author keywords

5 fluorouracil (5 FU); Capecitabine; Colorectal; Elderly; Irinotecan; Oxaliplatin; Raltitrexed; UFT

Indexed keywords

CAPECITABINE; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; INTERFERON; IRINOTECAN; LEVAMISOLE; METHOTREXATE; OXALIPLATIN; RALTITREXED; TEGAFUR; UFT; URACIL;

ABDOMINAL PAIN; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ANOREXIA; ASTHENIA; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; COLORECTAL CANCER; COMORBIDITY; DEHYDRATION; DIARRHEA; DRUG ABSORPTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ELIMINATION; DRUG FATALITY; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEBRILE NEUTROPENIA; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL TOXICITY; GERIATRIC PATIENT; HAND FOOT SYNDROME; HUMAN; INFECTION; LARYNX SPASM; LETHARGY; LEUKOPENIA; LIFE EXPECTANCY; LIVER TOXICITY; LUNG EMBOLISM; METASTASIS; MUCOSA INFLAMMATION; NAUSEA; NEUROTOXICITY; NEUTROPENIA; PERIPHERAL NEUROPATHY; RECURRENT CANCER; REVIEW; SENSORY NEUROPATHY; STOMATITIS; THROMBOCYTOPENIA; VEIN THROMBOSIS; VOMITING;

AGE FACTORS; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; COLORECTAL NEOPLASMS; COMORBIDITY; FEMALE; FLUOROURACIL; HEALTH STATUS; HUMANS; LIFE EXPECTANCY; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS;

EID: 27944443289     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/14740338.4.6.1041     Document Type: Review

References (51)

1. POPESCU RA, NORMAN A, ROSS PJ et al.: Adjuvant or palliative chemotherapy for colorectal cancer in patients 70 years or older. J. Clin. Oncol. (1999) 17:2412-2418.
2. BALDUCCI L, BEGHE C: The application of the principles of geriatrics to the management of the older person with cancer. Crit. Rev. Oncol. Hematol. (2000) 35:147-154.
3. MILLNER MD, PARADIS CF, HOUCK PR et al.: Rating chronic medical illness burden in geropsychiatric practice and research: application of the cumulative illness rating scale. Psychiatry Res. (1992) 41:237-248.
4. REPETTO L, FRATINO L, AUDISIO RA et al.: Comprehensive geriatric assessment adds information to Eastern cooperative oncology group performance status in elderly cancer patients: an Italian group for geriatric oncology study. J. Clin. Oncol. (2002) 20:4914-502.
5. KÖHNE CH, GROTHEY A, BOKEMEYER C, BONTKE N, AAPRO M: Chemotherapy in elderly patients with colorectal cancer. Ann. Oncol. (2001) 12:435-442.
6. SARGENT DJ, GOLDBERG RM, JACOBSON SD et al.: A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N. Engl. J. Med. (2001) 345:1091-1097.
7. DIASIO RB, HARRIS BE: Clinical pharmacology of 5-fluorouracil. Clin. Pharmacokinet. (1989) 16:215-237.
8. FLEMING FG, SCHILSKY RL: Phase I and pharmacological study of 5-fluorouracil in patients with hepatic and renal dysfunction. Proc. Am. Assoc. Cancer Res. (1993) 34:396.
9. MILANO G, ETIENNE MC, CASSUTO-VIGUIER E et al.: Influence of sex and age on fluorouracil clearance. J. Clin. Oncol. (1992) 10:1171-1175.
10. BERETTA G, BOLLINA R, COZZI C et al.: Should we consider the weekly chemotherapy with fluorouracil + racemic folinic acid a standard treatment for advanced/metastatic carcinoma of digestive tract in elderly patients? Proc. Am. Soc. Clin. Oncol. (1997) 16:259a.
11. DANIELE B, ROSATI G, TAMBARO R et al.: First-line chemotherapy with fluorouracil and folinic acid for advanced colorectal cancer in elderly patients: a phase II study. J. Clin. Gastroenterol. (2003) 36:228-233.
12. MATTIOLI R, LIPPE P, RECCHIA F et al.: Advanced colorectal cancer in elderly patients: tolerance and efficacy of leucovorin and fluorouracil bolus plus continuous infusion. Anticancer Res. (2001) 21:489-492.
13. FOLPRECHT G, CUNNINGHAM D, ROSS P et al.: Efficacy of 5-fluorouracil-based chemotherapy in elderly patients with metastatic colorectal cancer: a pooled analysis of clinical trials. Ann. Oncol. (2004) 15:1330-1338.
14. CUNNINGHAM D, ZALCBERG J, RATH U et al.: Final results of a randomised trial comparing 'Tomudex' (raltitrexed) with 5-fluorouracil plus leucovorin in advanced colorectal cancer. Ann. Oncol. (1996) 7:961-965.
15. NO AUTHORS LISTED: Drug-company decision to end cancer trial. Lancet (1999) 354:1045.
16. KÖHNE CH, THUSS-PATIENCE P, FRIEDRICH M et al.: Raltitrexed (Tomudex): An alternative drug for patients with colorectal cancer and 5-fluorouracil associated cardiotoxicity. Br. J. Cancer (1998) 77:973-977.
17. MEL JR, FELIU J, CAMPS C et al.: Tomudex (Raltitrexed) in elderly patients with advanced colorectal cancer: an effective palliative treatment. Proc. Am. Soc. Clin. Oncol. (2000) 19:257a.
18. FACCHINI T, GENET D, BERDAH JF et al.: Raltitrexed (Tomudex) has a manageable toxicity profile in elderly patients with metastatic colorectal cancer: final analysis of a multicentre study. Proc. Am. Soc. Clin. Oncol. (2000) 19:298a.
19. RUSTUM YM: Mechanism-based improvement in the therapeutic selectivity of 5-FU prodrug alone and under conditions of metabolic modulation. Oncology (1997) 54(Suppl. 11):7-11.
20. HOFF PM, PAZDUR R, BENNER SE et al.: UFT and leucovorin: a review of its clinical development and therapeutic potential in the oral treatment of cancer. Anticancer Drugs (1998) 9:479-490.
21. PAZDUR R, DOUILLARD JY, SKILLINGS JR et al.: Multicenter phase III study of 5-fluorouracil (5-FU) or UFT™ in combination with leucovorin (LV) in patients with metastatic colorectal cancer. Proc. Am. Soc. Clin. Oncol. (1999) 18:263a.
22. CARMICHAEL J, POPIELA T, RADSTONE D et al.: Randomized comparative study of ORZEL (oral uracil/tegafur (UFT)™) plus leucovorin (LV) versus parenteral 5-fluorouracil (5-FU plus IV) in patients with metastatic colorectal cancer. Proc. Am. Soc. Clin. Oncol. (1999) 18:264a.
23. DIAZ-RUBIO E, SASTRE J, ABAD A et al.: UFT plus or minus calcium folinate for metastatic colorectal cancer in older patients. Oncology (1999) 13:35-40.
24. FELIU J, GONZALEZ BARON M, ESPINOSA E et al.: Uracil and tegafur modulated with leucovorin: An effective regimen with low toxicity for the treatment of colorectal carcinoma in the elderly. Oncopaz Cooperative Group. Cancer (1997) 79:1884-1889.
25. POPA EC, LUO W, HOCHSTER H et al.: A phase II study of orzel (UFT+leucovorin) in elderly (≥ 75 years old) patients with colorectal cancer: results of ECOG 1299. Proc. Am. Soc. Clin. Oncol. (2005) 24:273s.
26. TWELVES C, GLYNNE-JONES R, CASSIDY J et al.: Effect of hepatic dysfunction due to liver metastases on the pharmacokinetics of capecitabine and its metabolites. Clin. Cancer Res. (1999) 5:1696-1702.
27. VAN CUTSEM E, FINDLAY M, OSTERWALDER B et al.: Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: results of a randomized phase II study. J. Clin. Oncol. (2000) 18:1337-1345.
28. HOFF PM, ANSARI R, BATIST G et al.: Comparison of oral capecitabine (Xeloda) versus intravenous 5-fluorouracil plus leucovorin (Mayo Clinic regimen) as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J. Clin. Oncol. (2001) 19:2282-2292.
29. TWELVES C, HARPER P, VAN CUTSEM E et al.: A phase III trial (SO14796) of Xeloda™ (capecitabine) in previously untreated advanced/metastatic colorectal cancer. Proc. Am. Soc. Clin. Oncol. (1999) 18:263a.
30. CRIPPS MC, VINCENT M, JONKER D et al.: Dose reduced first-line capecitabine monotherapy in older and less fit patients with advanced colorectal cancer. Proc. Am. Soc. Clin. Oncol. (2005) 24:265s.
31. DOUILLARD JY, CUNNINGHAM D, ROTH AD et al.: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet (2000) 355:1041-1047.
32. SALTZ LB, COX JV, BLANKE C et al.: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. (2000) 343:905-914.
33. PAZDUR R, ZINNER R, ROTHENBERG M et al.: Age as a risk factor in irinotecan (CPT-11) treatment of 5-FU-refractory colorectal cancer. Proc. Am. Soc. Clin. Oncol. (1997) 16:260a.
34. SCHAAF LJ, ICHHPURANI N, ELFRING GL et al.: Influence of age on the pharmacokinetics; of irinotecan (CPT-11) and its metabolites, SN-38 and SN-38 glucuronide (SN-38G), in patients with previously treated colorectal cancer. Proc. Am. Soc. Clin. Oncol. (1998) 16:202a.
35. STEWART G, CHAU I, NORMAN AR et al.: Elderly patients with fluoropyrimidine-resistant advanced colorectal cancer (CRC) derive similar benefit without excessive toxicity when treated with irinotecan monotherapy. Proc. Am. Soc. Clin. Oncol. (2004) 23:276.
36. ROTHENBERG ML, COX JV, DEVORE RF et al.: A multicenter, phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma. Cancer (1999) 85:786-795.
37. BOLLINA R, TONIOLO D, BELLONI P et al.: Oxaliplatin and irinotecan: phase I/II study in 5FU refractory advanced colorectal cancer elderly patients, a second line treatment. Proc. Am. Soc. Clin. (2001) 20:407a.
38. SASTRE J, MARCUELLO E, MASUTTI B et al.: Irinotecan in combination with fluorouracil in a 48-hour continuous infusion as first-line chemotherapy for elderly patients with metastatic colorectal cancer: a Spanish cooperative group for the treatment of digestive tumors study. J. Clin. Oncol. (2005) 23:3545-3551.
39. BOTTO HG, BOTTO ME: Combination of irinotecan and 5-fluorouracil, leucovorin in first and second line treatment in elderly patients with metastatic colo-rectal cancer. Proc. Am. Soc. Clin. Oncol. (2005) 24:306s.
40. FIORENTINI G, DENTICO P, CANTORE M et al.: Capecitabine plus irinotecan as second-line treatment (XELIRI) for metastatic colorectal cancer in elderly patients: Feasibility and safety results from a phase II study. Proc. Am. Soc. Clin. Oncol. (2005) 24:289s.
41. RAYMOND E, FAIVRE S, WOYNAROWSKI JM, CHANEY SG: Oxaliplatin: mechanism of action and antineoplastic activity. Semin. Oncol. (1998) 25(Suppl. 5):4-12.
42. DE GRAMONT A, FIGER A, SEYMOUR M et al.: Leucovorin and fluorouracil with or without oxaliplatin as first line treatment in advanced colorectal cancer. J. Clin. Oncol. (2000) 18:2938-2947.
43. BERRETTA A, BUONADONNA A, RUPOLO M et al.: Comparison between elderly and non-elderly patients of efficacy and tolerability of FOLFOX2 schedule in advanced colorectal cancer. Proc. Am. Soc. Clin. Oncol. (2001) 20:111b.
44. COMELLA P, GAMBARDELLA A, FARRIS A et al.: A tailored regimen including capecitabine and oxaliplatin for treating elderly patients with metastatic colorectal carcinoma. Southern Italy Cooperative Oncology Group trial 0108. Crit. Rev. Oncol. Hematol. (2005) 53:133-139.
45. TWELVES C, BUTTS C, CASSIDY J et al.: XELOX (capecitabine plus oxaliplatin), a safe and active first-line regimen for elderly patients with metastatic colorectal cancer (MCRC): Post-hoc analysis of a large phase II study. Proc. Am. Soc. Clin. Oncol. (2004) 23:259.
46. LÓPEZ-GÓMEZ L, ESCUDERO P, YUBERO A et al.: XELOX (capecitabine and oxaliplatin) as 1st line treatment for elderly patients (pts) with advanced/metastatic colorectal cancer (MCRC). Proc. Am. Soc. Clin. Oncol. (2004) 23:292.
47. SALUD A, ESCUDERO P, FELIÚ J et al.: XELOX (capecitabine and oxaliplatin) as 1st line treatment for elderly patients with advanced/metastatic colorectal cancer. Proc. Am. Soc. Clin. Oncol. (2005) 24:276s.
48. COMANDONE A, POCHETTINO P, BERGNOLO P et al.: Capecitabine and oxaliplatin: A phase II study with a new schedule of administration in elderly patients with advanced colorectal cancer. Proc. Am. Soc. Clin. Oncol. (2005) 24:291s.
49. ROSATI G, CORDIO S, TUCCI A et al.: Phase II trial of oxaliplatin and tegafur/uracil and oral folinic acid for advanced or metastatic colorectal cancer in elderly patients. Oncology (2005) 69:122-129.
50. MASSACESI C, LIPPE P, RECCHIA F et al.: Bi-fractionated oxaliplatin plus 5-fluorouracil/leucovorin for elderly patients with advanced colorectal cancer. Proc. Am. Soc. Clin. Oncol. (2005) 24:275s.
51. OH DY, KIM YJ, HAN SW et al.: Efficacy of reduced dose intensity FOLFOX-4 as first line palliative chemotherapy in elderly patients with advanced colorectal cancer. Proc. Am. Soc. Clin. Oncol. (2005) 24:300s.